CIGE0250011E1. An open-label extension to assess longterm safety and tolerability of omalizumab treatment in adolescents and adults with severe allergic asthma who participated in the 32-week core study.

Authors
Category Primary study
Registry of TrialsNovartis
Year Not known
This article has no abstract
Epistemonikos ID: 968c7a40ca903308fcd90ec4cf2f686b30a56bca
First added on: Sep 14, 2017